RFK Jr.'s Peptide Plan Explained, Why Most Substances Already Cleared but Few Are Fully Approved
A class of injectable drugs that biohackers, athletes and celebrities have been buying through gray-market vendors for years may soon have a legal path through compounding pharmacies. Whether that path is as wide as the headlines suggest is another question, and the answer affects anyone weighing peptide therapy for skin, recovery or anti-aging.
On “The Joe Rogan Experience” podcast in February 2026, Health and Human Services Secretary Robert F. Kennedy Jr. said roughly 14 of the 19 peptides the FDA restricted in 2023 would return to legal compounding status. Reporting from Pharmacy Times and the Associated Press has since filled in the picture, and the FDA’s own advisory committee schedule tells a narrower story.
These same compounds already show up as some of the priciest line items on typical biohacking clinic menus, which is part of why this regulatory fight matters to anyone pricing out a visit.
What RFK Jr. Actually Announced About Peptides
Kennedy’s announcement covered peptides the FDA moved to Category 2 in late 2023, a restricted status that effectively pulled them off compounding pharmacy shelves. The agency cited safety concerns and a lack of human trial data at the time.
Under Kennedy’s plan, named peptides expected to return to Category 1 include the following: BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, Selank, Semax, KPV and MOTS-C.
What’s actually still restricted right now is a shorter and different list than what’s been widely reported: GHRP-2, GHRP-6, Ibutamoren mesylate and Kisspeptin-10. Melanotan II and PEG-MGF, despite earlier reports describing them as likely holdouts, have also had their nominations withdrawn.
Reclassification governs compounding legality, not FDA drug approval. None of these peptides have completed phase 1 through 3 trials for the uses they’re commonly marketed for, like injury recovery, skin tightening or fat loss.
Why the FDA Restricted These Peptides in 2023
The 2023 move into Category 2 reflected the FDA’s view that the bulk powders compounding pharmacies use to mix these injections didn’t have enough safety data to support routine use.
Some peptides on the list have shown promise in animal studies, though human testing has lagged behind, BPC-157 among them, with only a handful of small human trials despite extensive animal data.
That gap is part of why critics remain skeptical. In a STAT First Opinion piece, UC Davis stem cell researcher Paul Knoepfler argued that loosening compounding rules without new clinical data shifts risk onto patients, warning that the policy direction worries him. Pharmacy Times itself frames this as a divide where reasonable people disagree on whether the original restriction was appropriate or an overreach, without landing on one side.
What’s Actually on the FDA Calendar in 2026
Headlines have compressed Kennedy’s announcement into “peptides are legal again,” but no FDA rule has formally changed. No Federal Register notice has gone out. No statute has been amended.
The FDA’s Pharmacy Compounding Advisory Committee agenda for July 23 and 24, 2026 lists a smaller set of substances actually under review. Only four substances appear on the first day’s agenda: BPC-157, KPV, TB-500 and MOTS-C. Emideltide, Semax and Epitalon are on the second day. That’s seven substances, not 14.
Reports also differ on dates. Some accounts cite an April 23, 2026 effective date, while the FDA’s own docket shows substances still moving through review months later. Saying “14 peptides are legal now” overstates where things actually stand.
What This Means for Patients and the Wellness Market
Even reclassified peptides still require a prescription from a licensed physician and a licensed compounding pharmacy to mix them. This isn’t an over-the-counter market. The gray-market vendors selling vials for $300 to $600 each, as reported by the Associated Press, operate outside that process regardless of how the FDA classifies the underlying substance.
Demand has been growing anyway. Jennifer Aniston has talked publicly about weekly peptide injections for her skin and serves as a paid spokesperson for a peptide supplement company. Joe Rogan has repeatedly discussed using BPC-157 for injury recovery. Wellness clinics now charge membership fees running into the thousands monthly for protocols built around these compounds.
For anyone considering peptide therapy, the practical takeaway is that the legal landscape is shifting but not settled. A physician working with a reputable compounding pharmacy is one path. Buying unmarked vials online is a different one, and reclassification doesn’t change the risk profile of products that were never tested in the first place.
This article was created by content specialists using various tools, including AI.
